Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance
-
- Markolf Hanefeld
- From the Centre for Clinical Studies (M.H, C.K., E.H., T.T.-K.) and Institute and Outpatient Department for Clinical Metabolic Research (F.S.), Dresden Technical University, Dresden, Germany; Research Centre-CHUM-Hotel-Dieu (J.L.C.), Montreal, Canada.
-
- Jean Louis Chiasson
- From the Centre for Clinical Studies (M.H, C.K., E.H., T.T.-K.) and Institute and Outpatient Department for Clinical Metabolic Research (F.S.), Dresden Technical University, Dresden, Germany; Research Centre-CHUM-Hotel-Dieu (J.L.C.), Montreal, Canada.
-
- Carsta Koehler
- From the Centre for Clinical Studies (M.H, C.K., E.H., T.T.-K.) and Institute and Outpatient Department for Clinical Metabolic Research (F.S.), Dresden Technical University, Dresden, Germany; Research Centre-CHUM-Hotel-Dieu (J.L.C.), Montreal, Canada.
-
- Elena Henkel
- From the Centre for Clinical Studies (M.H, C.K., E.H., T.T.-K.) and Institute and Outpatient Department for Clinical Metabolic Research (F.S.), Dresden Technical University, Dresden, Germany; Research Centre-CHUM-Hotel-Dieu (J.L.C.), Montreal, Canada.
-
- Frank Schaper
- From the Centre for Clinical Studies (M.H, C.K., E.H., T.T.-K.) and Institute and Outpatient Department for Clinical Metabolic Research (F.S.), Dresden Technical University, Dresden, Germany; Research Centre-CHUM-Hotel-Dieu (J.L.C.), Montreal, Canada.
-
- Theodora Temelkova-Kurktschiev
- From the Centre for Clinical Studies (M.H, C.K., E.H., T.T.-K.) and Institute and Outpatient Department for Clinical Metabolic Research (F.S.), Dresden Technical University, Dresden, Germany; Research Centre-CHUM-Hotel-Dieu (J.L.C.), Montreal, Canada.
抄録
<jats:p> <jats:bold> <jats:italic>Background and Purpose—</jats:italic> </jats:bold> Impaired glucose tolerance (IGT)–a prediabetic state–is an important risk factor for atherosclerosis. Acarbose, an α-glucosidase inhibitor, was shown in the placebo-controlled prospective study to prevent noninsulin-dependent diabetes mellitus (STOP-NIDDM) trial to reduce the risk of diabetes by 36% in IGT subjects. This article reports on a placebo-controlled subgroup analysis of the STOP-NIDDM study to examine the efficacy of acarbose to slow progression of intima-media thickness (IMT) in subjects with IGT. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods—</jats:italic> </jats:bold> One hundred thirty-two IGT subjects were randomized to placebo (n=66) or acarbose (n=66) 100 mg 3 times daily; the study duration was at least 3 years, mean follow-up time 3.9 (SD 0.6) years. Carotid IMT was determined at study entry and the end of the trial. The intent-to-treat analysis included 56 subjects in the acarbose and 59 in the control group who had a baseline and endpoint measurement. </jats:p> <jats:p> <jats:bold> <jats:italic>Results—</jats:italic> </jats:bold> A significant reduction of the progression of IMT <jats:sub>mean</jats:sub> was observed in the acarbose group versus placebo. After an average time of 3.9 years, IMT <jats:sub>mean</jats:sub> increased by 0.02 (0.07) mm in the acarbose group versus 0.05 (0.06) mm in the placebo group ( <jats:italic>P</jats:italic> =0.027). The annual increase of IMT <jats:sub>mean</jats:sub> was reduced by ≈50% in the acarbose group versus placebo. Multiple linear regression revealed IMT progression as significantly related to acarbose intake. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> Acarbose slows progression of IMT in IGT subjects, a high-risk population for diabetes and atherosclerosis. This is the first placebo-controlled prospective subgroup analysis, demonstrating that counterbalancing of postprandial hyperglycemia may be vasoprotective. </jats:p>
収録刊行物
-
- Stroke
-
Stroke 35 (5), 1073-1078, 2004-05
Ovid Technologies (Wolters Kluwer Health)
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360011144648670976
-
- NII論文ID
- 30022680858
-
- ISSN
- 15244628
- 00392499
-
- データソース種別
-
- Crossref
- CiNii Articles